<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939065</url>
  </required_header>
  <id_info>
    <org_study_id>18-2602</org_study_id>
    <nct_id>NCT03939065</nct_id>
  </id_info>
  <brief_title>Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management</brief_title>
  <official_title>Sensor Augmented Pump (SAP) Therapy for Inpatient Cystic Fibrosis Related Diabetes (CFRD) Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research proposes a pilot study using the combination of continuous glucose monitor
      (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic
      fibrosis related diabetes (CFRD) management in the inpatient setting, with the aim of
      improving glycemic control.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 28, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in CGM percent time over 140 mg/dl</measure>
    <time_frame>through study completion, up to 3 weeks</time_frame>
    <description>Differences in percent time &gt;140 mg/dl on CGM between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function</measure>
    <time_frame>baseline and 1 week</time_frame>
    <description>Change in Pulmonary Function, FEV1 (percent and L), from admission to 1 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulatory markers of inflammation</measure>
    <time_frame>baseline and 1 week</time_frame>
    <description>∆hsCRP and ∆calprotectin from admission to 1 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>baseline and 1 week</time_frame>
    <description>Change in weight from admission to 1 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statstrip glucose</measure>
    <time_frame>through study completion, up to 3 weeks</time_frame>
    <description>glucose obtained from bedside glucometer (mg/dl)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>beta-cell function</measure>
    <time_frame>within 24 hours of admission</time_frame>
    <description>measures to be derived from oral glucose tolerance testing, including insulin and c-peptide area under the curve</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cystic Fibrosis-related Diabetes</condition>
  <condition>Cystic Fibrosis Pulmonary Exacerbation</condition>
  <condition>Cystic Fibrosis in Children</condition>
  <arm_group>
    <arm_group_label>Insulin Pump and CGM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care and CGM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sensor Augmented Pump Therapy</intervention_name>
    <description>Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.</description>
    <arm_group_label>Insulin Pump and CGM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard of Care with CGM</intervention_name>
    <description>Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.</description>
    <arm_group_label>Standard of Care and CGM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥8 years

          2. Confirmed diagnosis of CF by consensus guidelines [50]

          3. Diagnosis of CFRD based on American Diabetes Association and CFF criteria [51]

          4. Admission for pulmonary exacerbation

        Exclusion Criteria:

          1. Known type 1 or type 2 diabetes, monogenic diabetes (MODY)

          2. Critical illness requiring admission to the intensive care unit

          3. Admission for indications other than pulmonary exacerbation (ex. Distal intestinal
             obstructive syndrome, surgery)

          4. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebekah Miller</last_name>
    <phone>720-777-2163</phone>
    <email>rebekah.miller@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Chan, MD</last_name>
    <phone>720-777-0990</phone>
    <email>christinel.chan@childrenscolorado.org</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

